There were no differences between treatment groups in the primary efficacy endpoint of infarct size measured by creatine kinase MB fraction area under the curve ( AUC ) ( median @ , @ , @ , and @ ng h/mL in the placebo , delcasertib @ , @ , and @ mg/mL groups , respectively ) in the anterior STEMI cohort .